In a trial, HER2 and MUC1 specific CARs with CD3z and co-stimulatory molecule respectively within one T cell have been designed, which can eliminate tumor cells efficiently and offset tumor antigen escape variants when encountering target cells co-expressing MUC1 and HER2 [62]. Here, CD247 is linked to neoplasm.